Diabetes Profile (4)
A focused veterinary metabolic profile that combines current glucose status with short-term glycemic trend assessment and lipid evaluation, helping clinicians screen for diabetes mellitus, monitor diabetic control, and interpret dyslipidemic patterns more confidently.
High-value clinical uses
Useful for diabetic screening, monitoring of known diabetic patients, distinguishing stress hyperglycemia from sustained hyperglycemia, and evaluating lipid changes that often accompany endocrine and metabolic disease.
Core coverage
Immediate glucose status, average glycemic exposure over the prior 1-3 weeks, triglyceride burden, and cholesterol burden in one compact panel.
Panel advantage
Small, targeted, and fast to interpret. It gives better diabetic context than glucose alone and can be used for first-line screening or serial follow-up.
What this panel is for
The Diabetes Profile (4) is intended for veterinary cases where carbohydrate metabolism and diabetic status are the main clinical question. It is valuable when persistent polyuria, polydipsia, weight loss, unexplained hyperglycemia, suspected endocrine disease, or diabetic follow-up require more than a single glucose result. The panel strengthens interpretation by combining GLU as a current-point measurement with FRU as a short-term trend marker, while TG and CHOL help identify the dyslipidemic patterns that often accompany diabetes mellitus, insulin resistance, pancreatitis risk, cholestatic overlap, or other endocrine disorders.
Measured test items (4)
Sample, workflow, and handling
Specimen
Use serum or lithium heparin plasma according to validated analyzer workflow and local laboratory procedure.
Platform family
Structured in the same product style as the Celercare V / Pointcare V chemistry analyzer panel family.
Fasting preference
A fasting sample is often preferable when clinically feasible, especially for triglyceride and cholesterol interpretation, because recent feeding can increase lipemic interference and post-prandial lipid values.
Interpretive caution
Prompt separation from cells is important for glucose, while marked lipemia can complicate photometric chemistry interpretation and should be considered in result review.
- Glucose: delayed separation from cells can cause falsely low results.
- Fructosamine: interpret with caution in marked hypoproteinemia or hypoalbuminemia because abnormal protein status can influence the result.
- Triglycerides and cholesterol: fasting status, lipemia, endocrine disease, pancreatitis risk, and cholestatic patterns can all influence interpretation.
Clinical interpretation by analyte
GLU - current glucose status
GLU reflects the patient’s current blood glucose concentration at the moment of sampling. It is essential for screening hyperglycemia or hypoglycemia, but by itself it cannot reliably distinguish transient stress hyperglycemia from persistent diabetes mellitus.
FRU - short-term glycemic trend
FRU (fructosamine) estimates average glycemic exposure over roughly the previous 1-3 weeks because it reflects glycated serum proteins. It is especially useful when current glucose is difficult to interpret or when diabetic control is being monitored over time.
TG - triglyceride burden
TG helps identify hypertriglyceridemia associated with diabetes mellitus, post-prandial lipemia, pancreatitis risk, obesity, or endocrine disease. It adds valuable metabolic context to a hyperglycemic patient.
CHOL - cholesterol burden
CHOL supports assessment of dyslipidemia and can rise in diabetes, cholestasis, hypothyroidism, nephrotic states, and other endocrine or metabolic disorders. In a diabetic profile, it helps determine whether the patient has broader lipid disturbance rather than isolated glucose dysregulation.
Quick high / low interpretation guide
| Analyte | Main intent of use | When high may suggest | When low may suggest / key notes |
|---|---|---|---|
| GLU | Current glucose status | Diabetes mellitus, stress hyperglycemia, recent feeding, endocrine insulin resistance, corticosteroid effect | Insulin excess, sepsis, severe hepatic dysfunction, juvenile/toy-breed causes, delayed sample separation artifact |
| FRU | Average glycemic exposure over the previous 1-3 weeks | Sustained hyperglycemia, diabetes mellitus, poor diabetic control | Hypoproteinemia, hypoalbuminemia, improving control, some hyperthyroid states in cats; always interpret with protein status |
| TG | Lipid burden and diabetic dyslipidemia support | Diabetes mellitus, post-prandial lipemia, pancreatitis risk, obesity, endocrine disease, inherited hyperlipidemia | Low values are usually of limited clinical importance |
| CHOL | Broader dyslipidemia and metabolic screening | Diabetes mellitus, cholestasis, hypothyroidism, nephrotic syndrome, hyperadrenocorticism | Malabsorption, protein-losing states, severe hepatic dysfunction, shunting in the appropriate context |
Pattern-based diagnostic scenarios
1) Stress hyperglycemia more likely
GLU is increased but FRU remains within the expected range or only minimally changed. This pattern supports transient hyperglycemia from stress, excitement, catecholamine response, or recent feeding rather than sustained diabetes.
2) Sustained diabetes / poor control
GLU is increased and FRU is also increased. If TG and CHOL are high as well, the pattern becomes even more supportive of sustained diabetic or insulin-resistant metabolic disturbance.
3) Diabetic dyslipidemia
Hyperglycemia with increased TG and CHOL suggests broader metabolic disruption, often seen in poorly regulated diabetes, obesity-associated insulin resistance, or concurrent endocrine disease.
4) Improving diabetic control
Current GLU may be variable from timing, feeding, or insulin dosing, but a falling FRU on serial testing supports improving average glycemic control over recent weeks.
5) Currently normoglycemic but recently uncontrolled
GLU is near normal at sampling, yet FRU remains high. This can fit a treated diabetic patient, a recent fasting/insulin effect, or a patient whose current single-time glucose result understates the average recent burden.
6) Hypoglycemia concern
GLU is low. This requires prompt clinical attention and is interpreted alongside history, insulin exposure, sepsis risk, liver function, and emergency status rather than as a routine screening finding.
7) Fructosamine needs caution
A surprisingly low or normal FRU in a patient with otherwise convincing diabetic signs should trigger review of albumin, total protein, thyroid status, and recent treatment history before ruling out diabetes.
8) Lipid-focused metabolic follow-up
If TG and CHOL remain high even when glucose is better controlled, consider concurrent endocrine disease, obesity, pancreatitis risk, cholestatic disease, or breed-related hyperlipidemia rather than attributing everything to diabetes alone.
Reference intervals
Guideline values shown below are shared platform-style values only where overlapping chemistry IFUs support them. Each laboratory should validate or establish its own species-specific reference intervals, especially for fructosamine.
| Analyte | Dog | Cat | Notes |
|---|---|---|---|
| GLU | 70-143 mg/dL | 74-159 mg/dL | Shared platform-style guideline interval for overlapping analytes |
| FRU | Use local validated interval | Use local validated interval | Method- and population-specific; interpret with protein status |
| TG | 8.8-79.7 mg/dL | 8.8-79.7 mg/dL | Shared platform-style guideline interval for overlapping analytes |
| CHOL | 110-320 mg/dL | 65-225 mg/dL | Shared platform-style guideline interval for overlapping analytes |
Interference and reporting notes
Glucose handling
False lowering of glucose becomes more likely if the sample remains in contact with cells too long before separation.
Fasting matters
Post-prandial lipemia can complicate triglyceride interpretation and may influence overall assay quality in heavily lipemic samples.
Fructosamine context
FRU is best used as a trend tool together with glucose history, clinical signs, and protein status rather than as an isolated binary test.
Unexpected dyslipidemia
Marked TG or CHOL elevation should prompt consideration of concurrent endocrine, pancreatic, renal, or cholestatic disease in addition to diabetes.
Why this profile is valuable
This panel is valuable because it solves one of the most common diagnostic problems in metabolic medicine: a single glucose result is often not enough. By pairing immediate glucose with fructosamine and adding triglycerides plus cholesterol, the profile gives a more clinically useful view of whether hyperglycemia is transient or sustained, whether diabetic control is improving or worsening, and whether broader dyslipidemia is present. That makes it efficient for screening, case workup, and serial follow-up in daily veterinary practice.
References
Primary product / IFU references
- Tianjin MNCHIP Technologies Co., Ltd. Related Celercare V / Pointcare V chemistry analyzer IFU. Used for shared platform-style workflow, sample-type framing, and overlapping guideline reference intervals where applicable.